Beyond Air, Inc. (XAIR)
| Market Cap | 415.85M |
| Revenue (ttm) | 294,422 |
| Net Income (ttm) | -26.44M |
| Shares Out | 26.64M |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 603,285 |
| Open | 15.31 |
| Previous Close | 13.88 |
| Day's Range | 13.77 - 15.66 |
| 52-Week Range | 4.62 - 15.83 |
| Beta | -0.49 |
| Analysts | Buy |
| Price Target | 15.40 (-1.3%) |
| Earnings Date | Nov 11, 2021 |
About XAIR
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Ther...
Financial Performance
In 2020, Beyond Air's revenue was $873,190, a decrease of -37.19% compared to the previous year's $1.39 million. Losses were -$22.87 million, 14.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Beyond Air stock is "Buy." The 12-month stock price forecast is 15.40, which is a decrease of -1.35% from the latest price.
News
3 Small-Cap COVID Stocks With Huge Upside
Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.
Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement
Beyond Air® retains 80% equity ownership of Beyond Cancer™, reaching the maximum allowable allotment of committed capital Beyond Air® retains 80% equity ownership of Beyond Cancer™, reaching the maximum...
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022
U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth quar...
Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond Air® to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
GARDEN CITY, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...
Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time
Beyond Air Reports Interim Data Of Self-Administered Inhaled NO For Lung Disease
Beyond Air Inc (NASDAQ: XAIR) has announced interim data from Australia's ongoing LungFit GO pilot study. Related: Beyond Air Issues Regulatory Update For LungFit PH System.
Beyond Air Issues Regulatory Update For LungFit PH System
Beyond Air Inc (NASDAQ: XAIR) announced a regulatory update for the approval process of its LungFit PH system. The Company said that the FDA facility inspections are currently ongoing.
Beyond Air® Provides Global Regulatory Update for LungFit® PH
FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval
Beyond Air® to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
GARDEN CITY, N.Y., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...
Beyond Air® Announces CFO Transition
GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -63.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air: Q1 Earnings Insights
Shares of Beyond Air (NASDAQ:XAIR) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 22.50% year over year to ($0.31), which missed the e...
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022
U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of calendar ...
Will Beyond Air, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond Air® Schedules First Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Call scheduled for Tuesday, August 10th at 4:30 pm Eastern Time Call scheduled for Tuesday, August 10th at 4:30 pm Eastern Time
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in July 2021
GARDEN CITY, N.Y., July 08, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...
Beyond Air (XAIR) is in Overbought Territory: What's Next?
Beyond Air (XAIR) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021
Submitted first premarket approval (PMA) application in the Company's history to FDA for LungFit ® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial l...
Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH
GARDEN CITY, N.Y., May 26, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the...
Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast
Call scheduled for Thursday, June 10th at 4:30 pm Eastern Time Call scheduled for Thursday, June 10th at 4:30 pm Eastern Time
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO ...
I nterim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit® PRO is well-tolerated with no...
Beyond Air® Appoints Peter Senior as Director of Business Development
Former Director of Healthcare Partnerships and External Relations at Linde plc brings 26 years of experience to Beyond Air Former Director of Healthcare Partnerships and External Relations at Linde plc ...
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021
GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...